New migraine combo drug shows promise for Tough-to-Treat patients

NCT ID NCT05550207

Completed Symptom relief Sponsor: Axsome Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new drug called AXS-07, which combines meloxicam and rizatriptan, for treating migraine attacks in adults. The 100 participants had previously not gotten enough relief from oral CGRP inhibitors. The goal was to see if the drug could relieve headache pain and other bothersome symptoms without needing rescue medication.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

AXS-07 (a combination of meloxicam and rizatriptan)

What this could lead to

If successful, this could provide a new acute treatment option for people with migraine who have not gotten relief from oral CGRP inhibitors.

What could go wrong

This is an open-label study with no placebo group, so results may be less reliable. The combination drug may cause side effects like dizziness or drowsiness.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

migraine disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MIGRAINE

Contacts and locations

Show contact details

Locations

Clinical Research Site

Colton, California, 92324, United States
Clinical Research Site

Fullerton, California, 92835, United States
Clinical Research Site

La Jolla, California, 92037, United States
Clinical Research Site

Los Angeles, California, 90067, United States
Clinical Research Site

Sherman Oaks, California, 91403, United States
Clinical Research Site

Stamford, Connecticut, 06905, United States
Clinical Research Site

DeLand, Florida, 32720, United States
Clinical Research Site

Hallandale, Florida, 33009, United States
Clinical Research Site

Hollywood, Florida, 33024, United States
Clinical Research Site

Miami, Florida, 33126, United States
Clinical Research Site

Ormond Beach, Florida, 31274, United States
Clinical Research Site

Oviedo, Florida, 32765, United States
Clinical Research Site

Pensacola, Florida, 32504, United States
Clinical Research Site

Winter Park, Florida, 32789, United States
Clinical Research Site

Stockbridge, Georgia, 30281, United States
Clinical Research Site

Avon, Indiana, 46123, United States
Clinical Research Site

Boston, Massachusetts, 02131, United States
Clinical Research Site

North Dartmouth, Massachusetts, 02747, United States
Clinical Research Site

Las Vegas, Nevada, 89102, United States
Clinical Research Site

Albuquerque, New Mexico, 87102, United States
Clinical Research Site

The Bronx, New York, 10466, United States
Clinical Research Site

Williamsville, New York, 14221, United States
Clinical Research Site

Philadelphia, Pennsylvania, 19114, United States
Clinical Research Site

Charleston, South Carolina, 29406, United States
Clinical Research Site

Knoxville, Tennessee, 37909, United States
Clinical Research Site

Nashville, Tennessee, 37203, United States
Clinical Research Site

Cypress, Texas, 77429, United States
Clinical Research Site

Sugar Land, Texas, 77478, United States
Clinical Research Site

Salt Lake City, Utah, 84107, United States
Clinical Research Site

Charlottesville, Virginia, 22911, United States
Clinical Research Site

McLean, Virginia, 22101, United States